Previous close | 1.4500 |
Open | 1.4000 |
Bid | 1.3400 x 100 |
Ask | 1.3900 x 100 |
Day's range | 1.3600 - 1.4300 |
52-week range | 1.2000 - 7.1300 |
Volume | |
Avg. volume | 950,751 |
Market cap | 9.241M |
Beta (5Y monthly) | 61.68 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.4200 |
Earnings date | 14 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 10.50 |
- Company to provide update on exciting new commercial agreement, as well as Phase 2 clinical trial in Spine and preclinical development program in Obesity - MELVILLE, N.Y., April 30, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it will release its first quarter 2024 financial results after market close on Tuesday, May 14, 2024. "I look forward
— Leading regenerative medicine and aesthetics innovators collaborate to build a vertically integrated, best-in-class biocosmeceutical platform — — Exclusive, five (5)-year agreement includes BioRestorative supplying its initial commercial product to Cartessa — — Financial impact from commercial partnership expected to provide flexibility for BioRestorative to become significantly less dependent on the capital markets for future funding — MELVILLE, N.Y., April 30, 2024 (GLOBE NEWSWIRE) -- BioRes
— Amendment replaces saline injections with sham injections in the control group — MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared an important amendment to the protocol of the ongoing Phase 2 study investigating the use of BRTX-100, the Company’s lead cell therapy